The Radiologists’ Role in Diagnosing Lung Toxicity from Anti-Cancer Drugs (2024)-WEB06-2024

Video Transcription

Video Summary

In this RSNA webinar, Nikolaus Gneidinger and Julian Dinkel discuss the role of radiologists in diagnosing lung toxicity from anti-cancer drugs. They aim to enhance the understanding of drug-induced lung toxicity, particularly focusing on radiology's role in identifying, monitoring, and managing this condition. They emphasize the importance of early diagnosis through effective communication between radiologists, oncologists, and pulmonologists. The webinar covers various drug-induced lung diseases, including pneumonitis, highlighting that radiological abnormalities are crucial for early detection, especially since symptoms such as dry cough and shortness of breath may initially be absent.<br /><br />The presenters also provide case studies demonstrating different patterns of drug-induced pneumonitis and discuss differential diagnosis. They stress the need for careful monitoring of patients, especially those with risk factors, using CT scans and other diagnostic tests. The webinar emphasizes the importance of a multidisciplinary approach for diagnosis and treatment, advising early intervention with steroids if drug-induced pneumonitis is suspected. Audience questions addressed concerns about scan radiation dosage, distinguishing pneumonitis from infections, and the timelines for pneumonitis development after treatment cessation. The session concludes by underscoring the collaborative efforts required among healthcare professionals to manage these complex cases effectively.

Keywords

radiology

lung toxicity

anti-cancer drugs

pneumonitis

early diagnosis

multidisciplinary approach

CT scans

case studies

drug-induced lung diseases